Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

TauRx Alzheimer’s Drug Fails in Late-Stage Trial

By Stephanie Guzowski | July 28, 2016

The recent results of a late-stage trial have delivered yet another hit to the Alzheimer’s scientific community.

TauRx’s experimental drug, LMTX, fared no better than a placebo at improving cognitive and functional skills in patients with mild to moderate Alzheimer’s disease. The Phase 3 study involved 891 patients.

The drug, LMTX, targets the protein tau, which is responsible for the tangles of nerve fibers that form in the brains of people with Alzheimer’s. For years, researchers targeted another protein, amyloid beta, which causes the sticky plaques associated with the disease — but these trials were unsuccessful in halting the progression of Alzheimer’s. Current treatments improve Alzheimer’s symptoms but no treatment has yet to slow the disease progression.

Despite these results, Dr. Ronald Petersen, of the Mayo Clinic told Reuters, “The notion that tau is still a very viable target for treatment in Alzheimer’s disease remains alive and well.”

LMTX, however, did show benefit in approximately 15 percent of patients who were not taking standard Alzheimer’s drugs. But more, larger trials will need to replicate these results to confirm that the drug can boost cognition as a monotherapy.

The treatment is currently being tested in a second study, involving about 700 people, with final results expected later this year.

Alzheimer’s disease affects more than 5 million Americans, and that number is projected to more than triple by 2050, according to the Alzheimer’s Association.


Filed Under: Drug Discovery

 

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50